Vascular Biogenics Ltd (VBLT) Stock
VBLT is no longer traded. Vascular Biogenics was delisted from the Nasdaq in November 2023.
Prices on this page are historical; the last trade was November 6, 2023 at $2.76.
Vascular Biogenics stock price history
VBLT final trading statistics
- Final close
- $2.76
- Final trading day
- Nov 6, 2023
- Market cap at delisting
- $12.11M
- Shares outstanding
- 77.64M
- Final 52-week range
- $0.10 – $5.27
- Avg. volume (final 3 mo.)
- 590,334
- All-time high (split-adj.)
- $568.05 · Jan 2015
- All-time low (split-adj.)
- $2.53 · Oct 2023
- Return since IPO
- -98.7%
- Beta
- 0.71
- Book value / share
- $0.27
- Price / book
- 10.10
Vascular Biogenics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $658.0K | -$32.2M | -$0.41 |
| FY2021 | $768.0K | -$28.7M | -$0.45 |
| FY2020 | $922.0K | -$24.3M | -$0.56 |
| FY2019 | $562.0K | -$19.8M | -$0.55 |
| FY2018 | $585.0K | -$20.5M | -$0.62 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Vascular Biogenics Ltd
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Vascular Biogenics stock FAQ
What happened to Vascular Biogenics stock?
Vascular Biogenics stock was delisted from the Nasdaq. Its final close was $2.76 on November 6, 2023.
Is VBLT stock still trading?
No. VBLT was delisted from the Nasdaq in November 2023 and no longer trades on a U.S. exchange.
What was the last price of VBLT stock?
VBLT closed at $2.76 on its final trading day, November 6, 2023, for a market value of about $12.11M.
What were Vascular Biogenics's revenue and earnings in its last full fiscal year?
Vascular Biogenics reported revenue of $658.0K and net income of -$32.2M in fiscal 2022, its last full year as a public company.
When did Vascular Biogenics go public?
Vascular Biogenics Ltd stock began trading on October 1, 2014.